Technical Analysis for AUPH - Aurinia Pharmaceuticals Inc
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 12.05 | 3.43% | 0.40 |
AUPH closed up 3.43 percent on Friday, May 20, 2022, on 1.11 times normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Support | Bullish | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Crossed Above 50 DMA | Bullish | 3.43% | |
Overbought Stochastic | Strength | 3.43% | |
Fell Below 50 DMA | Bearish | 7.49% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 7.49% | |
Calm After Storm | Range Contraction | 7.49% | |
Narrow Range Bar | Range Contraction | 7.49% | |
NR7 | Range Contraction | 7.49% | |
NR7-2 | Range Contraction | 7.49% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Up 3% | 2 days ago |
60 Minute Opening Range Breakout | 2 days ago |
Rose Above Previous Day's High | 2 days ago |
Up 2% | 2 days ago |
Up 1% | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2022
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, is engaged in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company's lead drug includes Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has a development and license agreement with 3SBio Inc. for the clinical development, registration, and commercialization of voclosporin in China; and licensing and collaboration agreement with Vifor Pharma for the treatment of lupus and various proteinuric nephrology indications. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Drugs Clinical Development Autoimmune Disease Peptides Lupus Immunosuppressants Nephrology Lupus Nephritis Nephritis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Drugs Clinical Development Autoimmune Disease Peptides Lupus Immunosuppressants Nephrology Lupus Nephritis Nephritis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 33.97 |
52 Week Low | 8.86 |
Average Volume | 2,067,579 |
200-Day Moving Average | 17.89 |
50-Day Moving Average | 11.42 |
20-Day Moving Average | 10.83 |
10-Day Moving Average | 10.82 |
Average True Range | 0.91 |
RSI | 55.75 |
ADX | 20.1 |
+DI | 24.91 |
-DI | 17.09 |
Chandelier Exit (Long, 3 ATRs) | 9.39 |
Chandelier Exit (Short, 3 ATRs) | 11.58 |
Upper Bollinger Bands | 12.28 |
Lower Bollinger Band | 9.37 |
Percent B (%b) | 0.92 |
BandWidth | 26.85 |
MACD Line | -0.04 |
MACD Signal Line | -0.28 |
MACD Histogram | 0.2349 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.49 | ||||
Resistance 3 (R3) | 13.35 | 12.73 | 13.25 | ||
Resistance 2 (R2) | 12.73 | 12.36 | 12.80 | 13.17 | |
Resistance 1 (R1) | 12.39 | 12.14 | 12.56 | 12.53 | 13.09 |
Pivot Point | 11.77 | 11.77 | 11.86 | 11.84 | 11.77 |
Support 1 (S1) | 11.43 | 11.40 | 11.60 | 11.57 | 11.01 |
Support 2 (S2) | 10.81 | 11.18 | 10.88 | 10.93 | |
Support 3 (S3) | 10.47 | 10.81 | 10.85 | ||
Support 4 (S4) | 10.61 |